CEACAM5 and metastatic malignant neoplasm in the lymph nodes: Taking account of either immune cell density or the tumor region, and with SVM algorithms to improve the accuracy, it comprehensively integrated information of eight TILs and myeloid cell IHC features (CD3IM, CD3CT, CD8IM, CD45ROCT, CD57IM, CD66bIM, CD68CT, and CD34), along with clinicopathologic features including patient sex, carcinoembryonic antigen (CEA) and lymph node metastasis (26).